The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus

J Manag Care Spec Pharm. 2020 Sep;26(9):1072-1076. doi: 10.18553/jmcp.2020.26.9.1072.

Abstract

Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Fazioli, Rind, and Pearson are employed by ICER. Gazauskas and Hansen have nothing to disclose.

MeSH terms

  • Administration, Oral
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / economics
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucagon-Like Peptides / administration & dosage*
  • Glucagon-Like Peptides / economics
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Hypoglycemic Agents / economics
  • Treatment Outcome

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • semaglutide
  • Glucagon-Like Peptides